Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 9/20 | 0.39 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23833199 | 1.00 | VCP (0.39) | VCPSMYD2CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL2914349 | 0.89 | RIPK1 (0.41) | SMYD2 | |
| SCHEMBL30192997 | 0.88 | ALDH1A1 (0.40) | SMYD2ALDH1A1GAANPC1RAB9A | |
| SCHEMBL27015413 | 0.88 | ALDH1A1 (0.40) | SMYD2ALDH1A1GAANPC1RAB9A | |
| SCHEMBL27183665 | 0.88 | SMYD2 (0.38) | SMYD2L3MBTL1 | |
| SCHEMBL28388395 | 0.85 | CYP4F2 (0.41) | SMYD2CYP4F2CYP4A11 | |
| SCHEMBL23833335 | 0.85 | SMYD2 (0.37) | SMYD2 | |
| SCHEMBL23517183 | 0.85 | SMYD2 (0.37) | SMYD2 | |
| SCHEMBL15822127 | 0.85 | SMYD2 (0.37) | SMYD2 | |
| SCHEMBL15822129 | 0.85 | SMYD2 (0.37) | SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4121055-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188696-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | VCP 3127/4885SMYD2 2720/4885CYP4F2 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.